A case‐control study on hormone therapy as a risk factor for breast cancer in Finland: Intrauterine system carries a risk as well
Open Access
- 8 July 2009
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 126 (2), 483-489
- https://doi.org/10.1002/ijc.24738
Abstract
The purpose of this study was to evaluate the association between postmenopausal hormone therapy (HT) and the risk for breast cancer in recently postmenopausal Finnish women. All Finnish women with first invasive breast cancer diagnosed between the ages of 50 and 62 years during 1995–2007 (n = 9,956) were identified from the Finnish Cancer Registry. For each case, 3 controls of the same age were retrieved from the Finnish Population Register. The cases and controls were linked to the national medical reimbursement register to assess the use of HT. The odds ratios (ORs) and 95% confidence intervals (CIs) for breast cancer were calculated with conditional logistic regression analysis, adjusting for parity, age at the first birth and health care district. Estradiol-only therapy (991 users with breast cancer, n) or oral progestagen (n = 138) was not accompanied by an increased risk. Estradiol-progestagen therapy (EPT) (n = 1,731) was associated with an elevated risk in the whole series (OR 1.36; 95% CI 1.27–1.46). The risk became detectable in less than 3 years of use. Continuous EPT use tended to be associated with a higher risk for breast cancer than the sequential EPT use. The use of tibolone (n = 80) (1.36; 1.15–1.96), a levonorgestrel-releasing intrauterine system (LNG–IUS) alone (n = 154) (1.45; 1.97–1.77) or as a complement to estradiol (n = 137) (2.15; 1.72–2.68) was also associated with an increased risk. The association between HT use and the risk for breast cancer shows a large variation between various forms of HT, and also the use of LNG-IUS may carry a risk.This publication has 26 references indexed in Scilit:
- Progestins in Hormone Replacement Therapies Reactivate Cancer Stem Cells in Women with Preexisting Breast Cancers: A HypothesisJournal of Clinical Endocrinology & Metabolism, 2008
- The Effects of Tibolone in Older Postmenopausal WomenThe New England Journal of Medicine, 2008
- Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort studyBreast Cancer Research and Treatment, 2007
- Hormone replacement therapy and incidence of hormone‐dependent cancers in the Norwegian Women and Cancer studyInternational Journal of Cancer, 2004
- Effects of Conjugated Equine Estrogen in Postmenopausal Women With HysterectomyJAMA, 2004
- Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in EuropeInternational Journal of Cancer, 2004
- Breast cancer and hormone-replacement therapy: the Million Women StudyThe Lancet, 2003
- Hormone replacement therapy containing progestins and given continuously increases breast carcinoma risk in SwedenCancer, 2003
- Intrauterine 10μg and 20μg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic responseBJOG: An International Journal of Obstetrics and Gynaecology, 2002
- Data Quality and Quality Control of a Population-Based Cancer Registry: Experience in FinlandActa Oncologica, 1994